1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
China Medical System Holdings Limited

China Medical System Holdings Limited

CHSYF
China Medical System Holdings LimitedUS flagOther OTC
1.57
USD
+0.00
- -
3.80BMarket Cap
China Medical System Holdings Limited
CHSYF
(Other OTC)

Recent

price

1.57

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.44
0.56
0.73
0.93
1.22
1.44
1.97
2.15
2.19
2.45
2.81
3.38
3.73
3.27
3.08
3.39
Revenue per Share
0.1
0.16
0.22
0.26
0.43
0.4
0.55
0.67
0.74
0.79
1.02
1.22
1.33
0.98
0.67
0.62
Basic EPS, GAAP
0.02
0.13
0.15
0.08
0.24
0.01
0.01
0.8
0.68
0.89
0.95
0.94
1.23
0.89
0.33
0.1
Free Cash Flow per Basic Share
0.02
0.07
0.07
0.1
0.12
0.15
0.19
0.25
0.29
0.33
0.34
0.47
0.52
0.55
0.23
0.27
Dividend per Share
0.02
0.02
0.03
0.03
0.79
1.01
1.32
1.7
2.11
2.58
0.03
0.03
4.73
5.34
5.79
6.13
Book Value per Share
0.65
0.47
0.62
0.77
0.96
1.19
0.8
1.3
1.8
2.16
2.84
3.3
3.96
4.4
4.68
5.1
Tangible Book Value per Share
1,982
2,373
2,415
2,415
2,415
2,467
2,487
2,487
2,486
2,480
2,472
2,468
2,454
2,452
2,427
2,420
Basic Weighted Avg Shares
877
1,322
1,759
2,249
2,945
3,553
4,901
5,349
5,433
6,074
6,946
8,337
9,150
8,013
7,469
8,212
Sales/Revenue/Turnover
26.26
29.5
32.45
28.3
30.8
30.06
31.46
35.53
37.04
39.57
40.46
38.58
39.84
35.34
23.2
19.99
Operating Margin (%)
10
26
33
37
42
78
176
196
199
204
208
220
227
230
259
267
Depreciation Expense
203
391
531
636
1,046
996
1,376
1,675
1,850
1,961
2,530
3,017
3,259
2,401
1,620
1,489
Net Income, GAAP
11.38
8.4
9.9
7.29
7.66
6.36
8.17
7.66
8.06
21.39
9.25
12.48
12.93
17.03
19.76
31.37
Effective Tax Rate (%)
23.14
29.6
30.17
28.29
35.51
28.03
28.08
31.31
34.05
32.28
36.43
36.19
35.62
29.96
21.69
18.13
Profit Margin (%)
1,248
988
1,235
1,372
757
1,211
155
2,301
2,564
2,005
4,067
5,298
5,952
6,746
7,189
7,829
Working Capital
- -
- -
- -
- -
- -
- -
- -
2,040
1,440
10
593
592
13
17
13
22
LT Debt
1,326
2,459
2,882
3,277
3,991
5,352
6,268
7,328
8,404
9,516
11,103
12,847
14,737
15,556
16,403
17,543
Total Equity
21.93
17.32
16.98
17.02
20.51
19.2
20.38
20.01
18.91
18.19
22.38
20.89
19.95
13.78
8.03
6.25
Return on Invested Capital (%)
123.16
206.26
131.2
142.27
75.93
37.68
35.46
30.92
29.19
28.86
63.92
229.49
42.49
17.55
11.27
10.1
Return on Capital (%)
209.11
884.4
794.83
766.76
105.05
45.29
47.62
44.5
38.98
33.64
77.98
3,574.89
55.74
19.45
11.94
10.32
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.7%
9.67%
6.95%
Free Cash Flow
1,194.02%
-26.25%
-69.97%
Net Income, GAAP
6.57%
-7.94%
-8.08%
Sales/Revenue/Turnover
9.53%
4.1%
9.95%
Total Cash Common Dividend
10.6%
3.04%
18.77%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
8,013
2024
- -
- -
- -
- -
7,469
2025
- -
- -
- -
- -
8,212

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.98
2024
- -
- -
- -
- -
0.67
2025
- -
- -
- -
- -
0.62

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.55
2024
- -
- -
- -
- -
0.23
2025
- -
- -
- -
- -
0.27
Similar Companies
Lincoln Pharmaceuticals Limited (LINCOLN.NS)
Swedencare AB (publ) (SWDCF)
Daito Pharmaceutical Co.,Ltd. (4577.T)
Origin Therapeutics Holdings Inc. (ORIG.CN)
Allied Biotech Corporation (1780.TWO)
Curaleaf Holdings, Inc. (CURA.TO)
Business
China Medical System Holdings Limited (CMS) is an investment holding company engaged in the marketing, promotion, sales, and production of pharmaceutical products, with a focus on linking pharmaceutical innovation and commercialization through strong product lifecycle management capabilities. The company offers a portfolio of marketed products spanning cardio-cerebrovascular and gastroenterology (including Plendil, Ursofalk, Salofalk, Imdur, and XinHuoSu); ophthalmology (including Augentropfen Stulln Mono Eye Drops, Lucentis, and Beovu); dermatology (including Hirudoid, Atopic Piel Series, and ruxolitinib cream); and medical aesthetics (including Vmonalisa), alongside innovative biologics and devices targeting unmet clinical needs in chronic and life-threatening diseases. CMS operates a mature commercialization platform compliant with international standards, featuring professional promotion teams, extensive channel resources, and expert networks, primarily serving hospitals, distributors, and wholesale customers. In recent developments, CMS filed for and completed a secondary listing on the Singapore Exchange mainboard in July 2025 under ticker 8A8.SG to expand its presence in Southeast Asia's pharmaceutical market, establishing CMS R&D in Singapore in 2024 for over 10 early-stage innovative drug projects. The company entered exclusive collaboration agreements in September 2025 with Chongqing Genrix Biopharmaceutical for innovative biologics Vecantoxatug and Silevimig injections used for passive immunization against tetanus; a distribution agreement in October 2025 with Novartis Pharma Services AG for ophthalmic drugs Ranibizumab (Lucentis) and Brolucizumab (Beovu) injections; and a January 2025 co-development and commercialization deal with Mabgeek Biotech for Class 1 innovative drug MG-K10, a long-acting anti-IL-4Rα monoclonal antibody for atopic dermatitis that achieved positive Phase III results. Additional milestones include NMPA acceptance of the new drug application for ZUNVEYL (benzgalantamine) for Alzheimer's disease in July 2025, regulatory approvals for clinical trials of povorcitinib (Jak1 inhibitor), CMS-D002 (GnRH antagonist for uterine fibroids), and other pipeline assets, contributing to H1 2025 revenue and profit growth amid strategic transformation. Founded in 1995 and incorporated in the Cayman Islands in 2006, CMS is headquartered at Unit 2106, 21/F, Island Place Tower, 510 King's Road, North Point, Hong Kong, and is a subsidiary of Treasure Sea Limited. The company primarily operates in Mainland China, with expanding activities in Hong Kong, Macau, Taiwan, Singapore, and broader Southeast Asia markets serving nearly 700 million people, supported by approximately 6,100 employees and a pipeline of about 40 differentiated innovative products, including 20 in-house R&D projects. CMS maintains leading academic and market positions in its specialty therapeutic areas through deep clinical insights, government affairs expertise, and a patient-centered approach.

Company News

APIChatGPT

  • defenseworld.net

    China Medical System (CHSYF) to Release Quarterly Earnings on Monday